AUPH Insider Trading

Insider Ownership Percentage: 4.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,888,411.85

Aurinia Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Aurinia Pharmaceuticals Share Price & Price History

Current Price: $7.85
Price Change: Price Increase of +0.03 (0.38%)
As of 05/14/2025 05:00 PM ET

This chart shows the closing price history over time for AUPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$7.85Closing price on 05/14/25:

SEC Filings (Institutional Ownership Changes) for Aurinia Pharmaceuticals (NASDAQ:AUPH)

36.83% of Aurinia Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AUPH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$27Mbought$4.40MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More on Aurinia Pharmaceuticals

Today's Range

Now: $7.85
Low: $7.48
High: $7.97

50 Day Range

MA: $8.03
Low: $7.20
High: $8.67

52 Week Range

Now: $7.85
Low: $5.08
High: $10.67

Volume

2,097,606 shs

Average Volume

1,340,328 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Who are the company insiders with the largest holdings of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' top insider shareholders include:
  1. Peter Greenleaf (CEO)
  2. Matthew Maxwell Donley (COO)
  3. Joseph M Miller (CFO)
  4. Scott Michael Habig (Insider)
  5. Greg Keenan (Insider)
  6. David RW Jayne (Director)
  7. Jeffrey Allen Bailey (Director)
  8. Joseph P Hagan (Director)
Learn More about top insider investors at Aurinia Pharmaceuticals.

Who are the major institutional investors of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' top institutional shareholders include:
  1. Nuveen LLC — 0.91%
  2. Jupiter Asset Management Ltd. — 0.55%
  3. Connor Clark & Lunn Investment Management Ltd. — 0.55%
  4. Charles Schwab Investment Management Inc. — 0.38%
  5. Segall Bryant & Hamill LLC — 0.27%
  6. Bank of New York Mellon Corp — 0.26%
Learn More about top institutional investors of Aurinia Pharmaceuticals stock.

Which institutional investors are selling Aurinia Pharmaceuticals stock?

During the last quarter, AUPH stock was sold by these institutional investors:
  1. Segall Bryant & Hamill LLC
  2. Charles Schwab Investment Management Inc.
  3. Simplex Trading LLC
  4. Jefferies Financial Group Inc.
  5. Invesco Ltd.
  6. Walleye Capital LLC
  7. SG Americas Securities LLC
  8. Alps Advisors Inc.
During the previous year, company insiders that have sold Aurinia Pharmaceuticals company stock include:
  1. Peter Greenleaf (CEO)
  2. Matthew Maxwell Donley (COO)
  3. Joseph M Miller (CFO)
  4. Scott Michael Habig (Insider)
  5. Greg Keenan (Insider)
  6. David RW Jayne (Director)
Learn More investors selling Aurinia Pharmaceuticals stock.

Which institutional investors are buying Aurinia Pharmaceuticals stock?

Within the previous quarter, AUPH stock was purchased by institutional investors including:
  1. Nuveen LLC
  2. Jupiter Asset Management Ltd.
  3. Rice Hall James & Associates LLC
  4. Hussman Strategic Advisors Inc.
  5. Connor Clark & Lunn Investment Management Ltd.
  6. Deutsche Bank AG
  7. GSA Capital Partners LLP
  8. EntryPoint Capital LLC